Andrea Cuartero-Martínez

Mrs. Andrea Cuartero-Martínez

IDIS, Santiago de Compostela, Galicia, Spain
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ana Castro BaladoAna Castro Balado
Ana Castro Balado
Enrique Bandín-VilarEnrique Bandín-Vilar
Enrique Bandín-Vilar
ACAndrea Cuartero-Martínez
Andrea Cuartero-Martínez
LGLaura García-Quintanilla
Laura García-Quintanilla
GHGonzalo Hermelo-Vidal
Gonzalo Hermelo-Vidal
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro
Cystinosis is a rare genetic disorder characterized by the accumulation of cystine crystals in different tissues and organs causing, among other symptoms, severe ocular manifestations. Cysteamine eye drops are prepared in hospital pharmacy departments to facilitate access to treatment, for which vehicles that provide adequate biopermanence, as well as adaptable containers that maintain its stability, are required. Difficulties related to cysteamine preparation, as well as its tendency to oxidize to cystamine, show the importance of conducting rigorous galenic characterization studies. This work aims to develop and characterize an ophthalmic compounded formulation of cysteamine prepared with hyaluronic acid and packaged in innovative single-dose systems. For this task, the effect of different storage temperatures and the presence/absence of nitrogen on the physicochemical stability of the formulation and its packaging was studied in a scaled manner, until reaching the optimal storage conditions. The results showed that 0.55% cysteamine, prepared with hyaluronic acid and packaged in single-dose containers, is stable for 30 days when stored at −20 °C. In addition, opening vials every 4 h at room temperature after 30 days of freezing maintains the stability of the cysteamine formulation for up to 16 h. Moreover, ocular biopermanence studies were conducted using molecular imaging, concluding that the biopermanence offered by the vehicle is not affected by the freezing process, where a half-life of 31.11 min for a hyaluronic acid formulation stored for 30 days at −20 °C was obtained, compared with 14.63 min for 0.9% sodium chloride eye drops.

5 June 2025 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
RVRubén Varela-Fernández
Rubén Varela-Fernández
Xurxo García-OteroXurxo García-Otero
Xurxo García-Otero
ACAndrea Cuartero-Martínez
Andrea Cuartero-Martínez
NGNoemí Gómez-Lado
Noemí Gómez-Lado
MGMiguel González-Barcia
Miguel González-Barcia
Francisco Otero-EspinarFrancisco Otero-Espinar
Francisco Otero-Espinar
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) for treating neovascular and oncological conditions, faces challenges in biodistribution and targeted delivery. Nanoparticle-based drug delivery systems have shown promise in enhancing the pharmacokinetic profiles of biologic drugs. This study aimed to develop and characterize bevacizumab-loaded PLGA nanoparticles to modify antibody’s distribution and improve its therapeutic efficacy. Characterization studies, morphological examination, release profile determination, stability and physical properties were conducted. Biodistribution was studied in rats using PET/CT imaging. Optimized nanoparticles were spherical (around 300 nm) and surface charge (about − 20 mV). Encapsulation efficiency and drug loading varied from 75 to 95%. Stability studies demonstrated minimal changes in size and drug content over the studied period. In vitro release exhibited a biphasic pattern, with an initial burst followed by a sustained release phase. In vivo pharmacokinetics and distribution revealed altered antibody distribution by encapsulation into nanoparticles. Safety studies indicated no significant cytotoxicity or adverse effects. The developed bevacizumab nanoparticles demonstrated favorable physicochemical characteristics, stability, and release profiles. These findings warrant further investigation in disease-specific models to elucidate the clinical potential of this nanoparticle-based delivery system for bevacizumab, particularly in enhancing anti-angiogenic effects and overcoming barriers to effective delivery in target tissues. Graphical abstract

26 July 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
ACAndrea Cuartero-Martínez
Andrea Cuartero-Martínez
Xurxo García-OteroXurxo García-Otero
Xurxo García-Otero
JCJessica Codesido
Jessica Codesido
NGNoemí Gómez-Lado
Noemí Gómez-Lado
JMJesús Mateos Martín
Jesús Mateos Martín
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro
Uveitis is a group of inflammatory ocular pathologies. Endotoxin-Induced Uveitis (EIU) model represent a well-known model induced by administration of Lipopolysaccharide (LPS). The aim is to characterize two models of EIU through two routes of administration with novel noninvasive imaging techniques. 29 rats underwent Intraocular Pressure (IOP) measurements, Optical Coherence Tomography (OCT), proteomic analysis, and Positron Emission Tomography and Computed Tomography (PET/CT). Groups included healthy controls (C), BSS administered controls (Ci), systemically induced EIU with LPS (LPSs), and intravitreally induced EIU with LPS (LPSi) for IOP, OCT, and proteomic studies. For 18F-FDG PET/CT study, animals were divided into FDG-C, FDG-LPSs and FDG-LPSi groups and scanned using a preclinical PET/CT system. LPSi animals exhibited higher IOP post-induction compared to C and LPSs groups. LPSi showed increased cellular infiltrate, fibrotic membranes, and iris inflammation. Proinflammatory proteins were more expressed in EIU models, especially LPSi. PET/CT indicated higher eye uptake in induced models compared to FDG-C. FDG-LPSi showed higher eye uptake than FDG-LPSs but systemic uptake was higher in FDG-LPSs due to generalized inflammation. OCT is valuable for anterior segment assessment in experimental models. 18F-FDG PET/CT shows promise as a noninvasive biomarker for ocular inflammatory diseases. Intravitreal induction leads to higher ocular inflammation. These findings offer insights for future inflammatory disease research and drug studies.

Verified
Journal Article
Open access
PDF file
MIMaría Puente Iglesias
María Puente Iglesias
ACAndrea Cuartero-Martínez
Andrea Cuartero-Martínez
RTRosario Touriño-Peralba
Rosario Touriño-Peralba
MRMaría Teresa Rodríguez-Ares
María Teresa Rodríguez-Ares
MFMaría Jesús Giráldez Fernández
María Jesús Giráldez Fernández
Ana Castro BaladoAna Castro Balado
Ana Castro Balado
Ophthalmic tacrolimus compounded formulations are usually made from the commercial intravenous presentation, which contains ethanol as a solubilizer due to the low solubility of tacrolimus. The use of cyclodextrins is presented as an alternative to ethanol, an ocular irritant excipient, to avoid its long-term irritant effects. Open-label, sequential, prospective study to compare effectiveness, safety, and adherence of a new formulation of 0.015% tacrolimus with cyclodextrins (TCD) versus 0.03% tacrolimus with ethanol (TE). The ocular evaluation was assessed by ocular signs, corneal staining, subjective questionnaires as Visual Function Questionnaire (VFQ-25) and Visual Analogue Scale (VAS) of symptoms, lacrimal stability, ocular redness, and intraocular pressure. Compliance was assessed by VAS of adherence and empirically (difference between theoretical and actual consumption). Clinical ocular signs and corneal staining score remained stable for most patients 3 months after switching formulations. The TCD formulation did not modify the tear stability and intraocular pressure of the treated patients compared to the TE formulation. TCD eye drops significantly decreased the subjective pain values on VFQ-25 scale and burning sensation on the VAS symptom scale in comparison to TE formulation after 3 months after the change to TCD formulation. The novel tacrolimus in cyclodextrins formulation is a promising alternative for treating inflammatory ocular pathologies refractory to first-line treatments.

5 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ana Castro BaladoAna Castro Balado
Ana Castro Balado
ACAndrea Cuartero-Martínez
Andrea Cuartero-Martínez
Hugo Pena-VerdealHugo Pena-Verdeal
Hugo Pena-Verdeal
GHGonzalo Hermelo-Vidal
Gonzalo Hermelo-Vidal
ASAnja Schmidt
Anja Schmidt
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro
Background: Cystinosis is a rare genetic disorder characterized by the accumulation of cystine crystals in several tissues and organs causing, among others, severe eye symptoms. The high instability of cysteamine eye drops makes it difficult to develop formulations with an acceptable shelf life to be prepared in hospital pharmacy departments. Previously, a new compounded formulation of cysteamine eye drops in hyaluronic acid (HA) packaged in innovative single-dose systems was developed. Methods: Long-term stability at −20 °C of this formulation was studied considering the content of cysteamine, pH, osmolality, viscosity, and microbiological analysis. The oxygen permeability of single-dose containers was also studied and an ocular biopermanence study was conducted in healthy volunteers measuring lacrimal stability and volume parameters. Results: Data confirm that cysteamine concentration remained above 90% for 120 days, all parameters remaining within the accepted range for ophthalmic formulations. The permeability of the containers was reduced over time, while ocular biopermanence was maintained despite the freezing process and storage time. Conclusions: 0.55% cysteamine hydrochloride formulation in HA and packaged in single-dose containers preserved at −20 °C is stable for 120 days protected from light, presenting high potential for its translation into clinical practice when commercial presentations are not available.

1 November 2022
Verified
Journal Article
Closed access
ACAndrea Cuartero-Martínez
Andrea Cuartero-Martínez
GHGonzalo Hermelo-Vidal
Gonzalo Hermelo-Vidal
Ana Castro BaladoAna Castro Balado
Ana Castro Balado
AGAngeles Gomez-Garcia
Angeles Gomez-Garcia
MGMiguel Gonzalez-Barcia
Miguel Gonzalez-Barcia
CMCristina Mondelo-García
Cristina Mondelo-García